Zoetis Inc. (ZTS) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BEARISH

The animal health market is expected to grow to $51.6 billion by 2034, driven by increased demand for preventive care, biotechnology advancements, and the humanization of pets. This expansion, currently led by North America, is also anticipated to see significant growth in the Asia-Pacific and European regions. These trends suggest a sustained positive outlook for companies operating within the animal health sector. Investors should monitor the pace of innovation in biotechnology and the continued adoption of preventive healthcare measures by pet owners.

Market Data

ZTS Stock Snapshot

Zoetis Inc. · Healthcare · zoetis.com

Zoetis Inc. is a global leader in animal health, focused on developing and delivering a comprehensive portfolio of medicines, vaccines, diagnostic products, and services for both livestock and companion animals. The company's core value proposition lies in its broad product offerings, spanning parasiticides, vaccines, and diagnostics, catering to a diverse range of species including cattle, swine, poultry, dogs, and cats. Zoetis commercializes its products through various channels, targeting veterinarians, livestock producers, and pet owners. This expansive reach, combined with its commitment to innovation, including a collaboration for novel antibiotic development, positions Zoetis as a key player in the growing animal health market. Founded in 1950, the company is headquartered in Parsippany, New Jersey.

ZTS is currently trading at $122.38, giving Zoetis Inc. a market cap of 51.58B and a P/E ratio of 19.3. Today's range spans $119.57–$122.97, with shares opening at $120.08 and moving down $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 73/100 (BUY) with a news sentiment reading of 40/100.

Over the past year ZTS has traded between $113.29 and $172.23 - the current price is +8.0% off the 52-week low and -28.9% from the high. 27 analysts cover the stock with a Hold consensus and a mean 12-month target of $150.29 (range $127.00–$190.00), implying upside of +22.8%.

Growth-oriented Healthcare investors looking for technical confirmation find it in ZTS: BUY signal, 73/100 score, bearish sentiment at 40/100, price $122.38 (near 52-week lows). The current P/E ratio stands at 19.3. The 51.58B market cap is the sweet spot - big enough to absorb institutional sizing, small enough to move materially on conviction. Annual range: $113.29–$172.23.

ZTS|EarningsZoetis Inc.

Earnings Summary

Zoetis Inc. (ZTS) is a global leader in animal health, operating within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. The company develops and delivers a wide array of medicines, vaccines, diagnostic products, and services for both livestock and companion animals, including parasiticides and vaccines. Zoetis targets veterinarians, livestock producers, and pet owners, positioning itself as a key player in the expanding animal health market. Examining recent quarterly performance, Zoetis has demonstrated strong EPS growth, with Q2 2025 reporting $1.76, a significant increase from $1.48 in Q1 2025. Revenue also followed an upward trend, reaching $2.46 billion in Q2 2025, up from $2.22 billion in Q1 2025. The company has a history of exceeding analyst estimates, beating EPS expectations in Q4 2024, Q1 2025, Q2 2025, and Q3 2025, and revenue expectations in Q4 2024, Q1 2025, Q2 2025, and Q4 2025. This consistent pattern of beats highlights strong financial execution. Recent news indicates that the animal health market is projected for significant growth, driven by preventive care and biotechnology advancements. Zoetis is strategically expanding its genomics capabilities through the acquisition of Neogen's Genomics business. However, one analyst firm has adjusted its price target downwards, maintaining a Market Perform rating, suggesting a cautious near-term outlook from that specific source. Investors will be watching for continued strong performance in the upcoming quarters, particularly how the integration of the acquired genomics business impacts future offerings and market position, and will monitor the overall growth trajectory of the animal health sector.

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$1.62	-	-
Q4'25	$1.62	$1.48	-8.4%
Q3'25	$1.62	$1.70	+4.8%
Q2'25	$1.61	$1.76	+9.2%
Q1'25	$1.40	$1.48	+5.8%
Q4'24	$1.36	$1.40	+2.8%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$2.3B	-	-
Q4'25	$2.3B	$2.4B	+3.1%
Q3'25	-	$2.4B	-
Q2'25	-	$2.5B	-
Q1'25	-	$2.2B	-
Q4'24	-	$2.3B	-

Technical Score (1D)

BUY

News Sentiment

BEARISH

Market Data

ZTS Stock Snapshot

Zoetis Inc. · Healthcare · zoetis.com

News Sentiment Analysis

Sentiment gathered from recent headlines

40/100

Strong NegativeNeutralStrong Positive

BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Zoetis (ZTS) is trading around $119, prompting a reassessment of its valuation following a significant share price decline over the past year. The stock has experienced a notable downturn, with an 18.8% drop over the last 12 months. This performance may lead investors to re-evaluate the risk-reward profile of the animal health giant. Current market sentiment suggests a need to scrutinize recent figures and industry checks to determine if the stock is still pricing in high expectations.

What did this article say?

Zoetis (ZTS) experienced a trading session close of $119.04, marking a 1.42% decrease from the previous day. This movement occurred while the broader market saw gains, suggesting potential underperformance for the animal health stock. Traders should monitor this divergence to understand the underlying pressures affecting ZTS. Further analysis is required to determine the catalysts behind this specific price action.

What did this article say?

Ahead of Zoetis' (ZTS) upcoming earnings release, market participants are focused on key performance indicators and potential future guidance. Analysts are closely monitoring the company's ability to maintain growth momentum in its diverse animal health portfolio. Investors should watch for commentary on product demand, R&D pipeline progress, and any strategic initiatives that could impact future revenue streams.

What did this article say?

This article suggests that recent stock performances may not fully reflect the underlying value or future potential of certain healthcare companies. Investors are advised to look beyond short-term trends when evaluating opportunities. The analysis implies a need for deeper due diligence in the healthcare sector.

What did this article say?

Citigroup has initiated coverage of Zoetis (ZTS) with a 'Buy' recommendation, signaling a positive outlook from the investment bank. The firm's initiation suggests confidence in ZTS's future performance and market position within the animal health sector. This move by a prominent analyst firm provides a new benchmark for investor sentiment and valuation.

What did this article say?

This analysis delves into the valuation of Zoetis (ZTS) as investors reassess the stock following a period of inconsistent returns. The article explores whether the current market price reflects the company's intrinsic value, considering its financial performance and future growth prospects. Investors are encouraged to scrutinize the underlying metrics to form an informed opinion on ZTS's investment potential.

What did this article say?

Citi has initiated coverage on Zoetis (ZTS) with a Buy rating and a $145 price target, designating it as their top pick within the animal health sector. The firm's bullish stance is underpinned by the strong trend of pet humanization, where owners increasingly view their animals as family members. This analyst upgrade signals potential upside for ZTS, driven by sustained consumer spending on pet care.

What did this article say?

The global animal health market is projected to expand from $40.1 billion in 2025 to $51.6 billion by 2034, reflecting a compound annual growth rate of 2.73%. Key growth drivers include the increasing demand for preventive healthcare, advancements in biotechnology, and the rising trend of pet humanization. North America currently leads the market, though significant growth is anticipated in the Asia-Pacific and European regions.

What did this article say?

Citigroup analyst Daniel Grosslight has initiated coverage on Zoetis (ZTS) with a 'Buy' rating. The firm has set a price target of $145 for the animal health company's stock. This initiation suggests a positive outlook from a new analyst covering the name.

What did this article say?

Leerink Partners has lowered its price target for Zoetis (ZTS) to $127 from $133. The firm has maintained its Market Perform rating on the stock. This adjustment reflects a reassessment of the company's valuation by the analyst firm.

ZTS|EarningsZoetis Inc.

Earnings Summary

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$1.62	-	-
Q4'25	$1.62	$1.48	-8.4%
Q3'25	$1.62	$1.70	+4.8%
Q2'25	$1.61	$1.76	+9.2%
Q1'25	$1.40	$1.48	+5.8%
Q4'24	$1.36	$1.40	+2.8%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$2.3B	-	-
Q4'25	$2.3B	$2.4B	+3.1%
Q3'25	-	$2.4B	-
Q2'25	-	$2.5B	-
Q1'25	-	$2.2B	-
Q4'24	-	$2.3B	-

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

ZTS·Zoetis Inc.

ZTS Stock Snapshot

Earnings | EPS

Revenue

ZTS·Zoetis Inc.

ZTS Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

News Sentiment Analysis

Recent News Coverage

ZTS·Zoetis Inc.

ZTS Stock Snapshot

Earnings | EPS

Revenue

ZTS·Zoetis Inc.

ZTS Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More